Reviva Pharmaceuticals Holdings, Inc. Warrant (RVPHW)

Overview

Reviva Pharmaceuticals Holdings, Inc. represents a progressive clinical-stage biopharmaceutical entity dedicated to the conception, advancement, and commercial delivery of pioneering therapeutics aimed at addressing the unmet medical requirements across various domains such as central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Founded in 2018 and headquartered in Cupertino, California, Reviva is at the forefront of tackling complex diseases with significant patient need.

Products and Services

Brilaroxazine (RP5063): This leading candidate underscores Reviva's innovative approach in the pharmaceutical landscape. Currently in Phase III clinical trials for schizophrenia treatment, brilaroxazine demonstrates a broad therapeutic potential across several conditions. Completed Phase I clinical trials confirm its application in bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder (ADHD), and additional neurological and psychiatric conditions, including behavioral and psychotic symptoms associated with dementia or Alzheimer's disease, Parkinson's disease psychosis, ADHD, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. This diversity in application showcases Reviva's commitment to addressing complex mental and physical health challenges.

RP1208: Still in the pre-clinical development phase, RP1208 represents Reviva’s ambition in expanding its therapeutic portfolio. Targeted at the treatment of depression and obesity, RP1208 holds promise for contributing solutions to these widespread health issues, further illustrating the company's dedication to broadening its impact on public health through innovative pharmaceutical developments.